<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1528">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04386447</url>
  </required_header>
  <id_info>
    <org_study_id>OsCOVID19</org_study_id>
    <nct_id>NCT04386447</nct_id>
  </id_info>
  <brief_title>Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19</brief_title>
  <acronym>OsCOVID19</acronym>
  <official_title>Phase II, Multicenter, Open-label, Rct With an Adaptive Design, to Assess Efficacy of Intravenous Administration of Oxytocin in Hospitalized Patients Affected by COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero-Universitaria di Parma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Parma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliero-Universitaria di Parma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction There are currently no treatments with demonstrated efficacy for COVID-19
      infection. Epidemiological evidence points to the existence of intrinsic protection factors
      which make young persons and women more resistant to the infection, whereas older patients
      with multiple illnesses, above all with heart disease, are at greatest risk. This trial
      proposes treatment initiated in the early stages of the disease, when clinical worsening is
      most likely, with intravenous Oxytocin (OT), an endogenous hormone currently safely used in
      clinical practice. The selection of this molecule is based on numerous experimental and
      clinical observations, which show its activity in modulating resistance to pathogens, in
      mitigating overall cardiovascular risk, and in acting on the production of Nitric Oxide (ON)
      in the lungs, which is emerging as a key therapeutic factor for the improvement of
      respiratory function in patients with SARS-COVID 19. Finally, OT is physiologically produced
      by the human body, especially in the female sex and in the age ranges that coincide with most
      resistant patients. In routine clinical practice, OT exhibits an excellent therapeutic index,
      in absence of significant adverse effects.

      Primary aim To assess the effects of Oxytocin in addition to standard therapy, with respect
      to Standard of Care (SoC), in reducing the number of patients who enter a critical stage
      Secondary aim

      To describe:

        -  Mortality 28 days after randomization

        -  Time to mechanical ventilation during the study

        -  Duration of dependency on oxygen supply

        -  Length of stay

        -  Temporal trend of clinical improvement (7-category ordinal scale)

        -  Safety analysis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intervention In addition to standard treatment, patients in the experimental arm will receive
      intravenous OT with dilution of 25 UI or 40 UI OT in 500cc physiological solution NaCl 9%. OT
      will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have
      the option to decrease infusion speed based on significant variations in arterial pressure,
      otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration
      will be 10 days

      Standard of Care (SoC). Standard of Care will comply with the indications of the
      Emilia-Romagna Region for the treatment of covid-19, and will include the following:

        -  Oxygen supply or non-invasive ventilation to target peripheral blood saturation &gt; 94%

        -  Hydroxychloroquine 200mg b.i.d w/o an initial 1-2 days loading dose of 400 mg bid for
           1-2 days (the dose may be reduced in patients with advanced CKD according to local
           protocols) or remdesivir 200 mg in.v on day 1, followed by a 100 mg q.d.

        -  Antiretroviral therapy (usually for 5 days) with lopinavir / ritonavir or darunavir /
           cobicistat is permitted

        -  Azithromycin 500 mg q.d., usually for 5 days, is permitted in patients with suspected
           bacterial superinfection, paying particular attention to safety, considering reports of
           risk of adverse events in association with hydroxychloroquine

        -  Prophylaxis for deep vein thrombosis

        -  Steroids are not routinely recommended but may be considered in selected patients.

      Study design Phase II, multicenter, open-label, experimental randomized controlled trial with
      an adaptive design, aiming to assess superiority of Oxytocin administration vs SoC.

      The adaptive design includes Stage 1, which aims to define the more active of the two
      considered OT doses, verify endpoints, the target population and the necessary sample size
      for the following Stage. Selection between the two considered doses (25 UI e 40 UI) will be
      based on the proportion of patients for which one of the conditions that make up the endpoint
      is recorded (see below). To this end, for each of the 2 dosages of the experimental agent, a
      single arm, single stage Fleming design will be applied. Patients enrolled in this Stage will
      be assigned by balanced randomization (1:1) to one of the two OT doses. The decisional
      algorithm requires that in a sample of 25 patients, at least 20 (80%) do not worsen to a
      critical stage (main endpoint) with respect to an expected 17 (68%) with only SOC.

      In Stage 2, patients in the experimental arm will receive the dose selected in Stage 1. The
      study, on two parallel groups, will use unbalanced randomization, because patients who
      received the selected dose in Stage 1 will be included in the experimental arm to achieve
      equal sample size between the two arms (60+60) for the analysis of final endpoints Sample
      size Stage 1 - sample is determined according to the single arm single stage Fleming design
      applied to each of the 2 investigated OT doses (25 and 40 UI). 25 patients for each dose are
      estimated necessary to demonstrate a statistically significant difference considering the
      one-tail test with an alpha probability of 10% and a statistical power of 80%.

      Stage 2 - determined using as comparison the test for proportions. From available data, it is
      assumed that during 14 days of hospitalization the proportion of patients in the SoC group
      who enters a critical stage (primary endpoint) is 30%, versus 12% in the experimental arm.
      Using a two-tail test, an alpha probability of 10% and a statistical power of 80%, was
      estimated that 60 patients per arm are necessary to demonstrate a statistically significant
      difference
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of cases who during 14 exhibit one of the following conditions</measure>
    <time_frame>14 days</time_frame>
    <description>Proportion of cases who during 14 days exhibit one of the following conditions (the most severe):
respiratory failure that requires mechanical ventilation
organ failure that requires intensive care monitoring and treatment
death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality 28 days after randomization</measure>
    <time_frame>28 days</time_frame>
    <description>Mortality 28 days after randomization</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">145</enrollment>
  <condition>Covid-19</condition>
  <condition>Corona Virus Infection</condition>
  <condition>SARS-CoV 2</condition>
  <arm_group>
    <arm_group_label>Oxytocin 40 UI + SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 40 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxytocin 25 UI + SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 25 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of Care (SoC). Standard of Care will comply with the indications of the Emilia-Romagna Region for the treatment of covid-19, and will include the following:
Oxygen supply or non-invasive ventilation to target peripheral blood saturation &gt; 94%
Hydroxychloroquine 200mg b.i.d w/o an initial 1-2 days loading dose of 400 mg bid for 1-2 days (the dose may be reduced in patients with advanced CKD according to local protocols) or remdesivir 200 mg in.v on day 1, followed by a 100 mg q.d.
Antiretroviral therapy (usually for 5 days) with lopinavir / ritonavir or darunavir / cobicistat is permitted
Azithromycin 500 mg q.d., usually for 5 days, is permitted in patients with suspected bacterial superinfection, paying particular attention to safety, considering reports of risk of adverse events in association with hydroxychloroquine
Prophylaxis for deep vein thrombosis
Steroids are not routinely recommended but may be considered in selected patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 25 UI or 40 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days</description>
    <arm_group_label>Oxytocin 25 UI + SOC</arm_group_label>
    <arm_group_label>Oxytocin 40 UI + SOC</arm_group_label>
    <other_name>Oxytocin OT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of Care (SoC). Standard of Care will comply with the indications of the Emilia-Romagna Region for the treatment of covid-19, and will include the following:
Oxygen supply or non-invasive ventilation to target peripheral blood saturation &gt; 94%
Hydroxychloroquine 200mg b.i.d w/o an initial 1-2 days loading dose of 400 mg bid for 1-2 days (the dose may be reduced in patients with advanced CKD according to local protocols) or remdesivir 200 mg in.v on day 1, followed by a 100 mg q.d.
Antiretroviral therapy (usually for 5 days) with lopinavir / ritonavir or darunavir / cobicistat is permitted
Azithromycin 500 mg q.d., usually for 5 days, is permitted in patients with suspected bacterial superinfection, paying particular attention to safety, considering reports of risk of adverse events in association with hydroxychloroquine
Prophylaxis for deep vein thrombosis
Steroids are not routinely recommended but may be considered in selected patients.</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>SOC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Diagnosis of pneumonia caused by COVID-19

          -  Respiratory and/or systemic symptoms and initial mild respiratory failure and with
             objective signs of lung involvement

          -  Respiratory frequency â‰¥25/min, blood oxygen saturation (SaO2) &lt; 95% in A-A, PaO2/FiO2
             ratio &lt; 300

          -  Hospital admission since less than 48 hours

          -  Signature of informed consent for study participation

        Exclusion Criteria:

          -  MEWS score &gt; 4

          -  Severe multiple organ failure

          -  Recent cardiomyopathy, unstable angina, acute myocardial infarction

          -  Severe kidney failure with glomerular filtration rate less than 30 ml/min or renal
             replacement therapy or peritoneal dialysis

          -  History of diabetes insipidus or severe hyponatremia (&lt;128 mEq/L) or hypernatremia
             (&gt;155 mEq/L)

          -  QT interval which in the opinion of the patient's treating physician contraindicates
             therapy with OT

          -  State of shock

          -  Women who are pregnant or nursing

          -  Known intolerance or hypersensitivity to the drug or its excipients

          -  Treatment with antirejection agents

          -  Individuals with severe liver failure

          -  Patients enrolled in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tiziana Meschi, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero-Universitaria di Parma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tiziana Meschi, MD,PhD</last_name>
    <phone>0521702083</phone>
    <email>tiziana.meschi@unipr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>CNRS</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pier Francesco Ferrari, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Angela Sirigu, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Tiziana Meschi, MD, PhD</last_name>
      <phone>0521702083</phone>
      <email>tiziana.meschi@unipr.it</email>
    </contact>
    <contact_backup>
      <last_name>Antonio Nouvenne, MD,PhD</last_name>
      <phone>0521702083</phone>
      <email>anuovenne@ao.pr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Giuseppe Maglietta, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caterina Caminiti, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Riccardo Volpi, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlo Ferrari, MD,Phd</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Nouvenne, MD,Phd</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorenzo Finardi, MD,Phd</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Francesco</name>
      <address>
        <city>Nuoro</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Gianluca Deiana, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Antonina Carai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Licia Abbruzzese, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peppino Paffi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero-Universitaria di Parma</investigator_affiliation>
    <investigator_full_name>Tiziana Meschi</investigator_full_name>
    <investigator_title>Director of the Geriatric Rehabilitation Medical Department</investigator_title>
  </responsible_party>
  <keyword>Covid-19</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Corona Virus Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

